The movement of enteric bacteria from the intestine to the blood and other organs is called translocation, a concept recognized clinically in the 1960s and defined experimentally in the 1980s. Translocation is a major precursor to the development of life-threatening bacteremia and sepsis, with a compromised immune system being a dominant risk factor. A significant cause of gut-derived sepsis is ExPEC, which clinically is the most frequently isolated Gram-negative pathogen from bacteremic patients. ExPEC is often multi-drug resistant, and there is evidence that such strains may be chronic colonizers of the GI tract. There is no vaccine. The mechanism by which ExPEC translocates out of the intestine has not been determined, and the bacterial factors needed for this process remain unknown. This funding period proposes to determine the importance of the pilus tip adhesin FimH in translocation. Preliminary data presented here suggests FimH is required for clinical strains of ExPEC to bind, invade, and pass through a transformed intestinal cell line. Hypothesizing that FimH is necessary for translocation in human hosts, we test here the requirements of FimH for passage through human intestinal enteroids and translocation in a murine model of leukopenia. In addition, we use these model systems, which our laboratory developed, to determine the molecular requirements of FimH-mediated translocation through enterocytes, the importance of FimH in globally circulating lineages of ExPEC, and if distinct FimH alleles dictate the efficiency of translocation. This work will determine if FimH is a viable target for preventing gut-derived sepsis in high-risk patients.

Public Health Relevance

Immunocompromised patients are at an elevated risk for developing infections of the blood from bacteria that live in their intestine. These infections begin through a process termed translocation, a multi-step event by which the bacteria move from the intestine to the blood. It is not understood if bacteria use certain molecular factors to translocate. In this project, one particular translocation factor that is important for binding intestinal cells is studied in hopes of providing new knowledge that will lead to medicines that prevent bacteria from translocating in high-risk patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI126354-02
Application #
9301468
Study Section
Special Emphasis Panel (ZRG1-IDM-B (80)S)
Program Officer
Ernst, Nancy Lewis
Project Start
2016-06-20
Project End
2018-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
2
Fiscal Year
2017
Total Cost
$198,125
Indirect Cost
$73,125
Name
Baylor College of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030